Literature DB >> 15083204

Overdiagnosis of breast cancer in Denmark.

P-H Zahl.   

Abstract

Entities:  

Mesh:

Year:  2004        PMID: 15083204      PMCID: PMC2409713          DOI: 10.1038/sj.bjc.6601738

Source DB:  PubMed          Journal:  Br J Cancer        ISSN: 0007-0920            Impact factor:   7.640


× No keyword cloud information.
Sir, Olsen claim in their article that organised mammography screening can operate without overdiagnosis of breast cancer. This paper contains no statistical analysis and does not report the number of detected cancers, so the readers can do the proper statistical analysis themselves. In particular, it does not report the incidence increase in per cent, and the readers are left to look at some figures. When I look at Figure 2, I read that the cumulative risk in Copenhagen increases from about 5.25% (1989–91) to 6.25% (1993–95). This gives 19% increase. Comparing the 5.75% cumulative risk on Fyn in 1992–93 to 6.75% cumulative risk in 1996–97 shows a 17% increase. There was some opportunistic screening before organised screening started in Denmark (Olsen ), so there is reason to attribute some of the incidence increase before 1993 to mammography. If cumulative risk in the second screening round is compared to the cumulative risk in 1987–89 (Copenhagen) or 1988–89 (Fyn), I get at least 30 and 50% incidence increases, respectively. The authors should also have studied incidence in the age group 70–74 years after some years with screening in the age group 50–69 years (Spix ). If mammography screening brings the time of diagnosis forward, incidence in the age group 70–74 years should decline. The difference between incidence increase in the age group 50–69 years and decline in the age group 70–74 years is the correct definition of overdiagnosis (Spix ). The authors do not report ductal carcinoma in situ (DCIS). On including DCIS (as Olsen and Gøtzsche (2001) did), one would assume that overdiagnosis today must be a much larger problem than reported by Olsen and Gøtzsche in the screening trials 20 years ago. In contrast, Etzioni recently reported only 30% overdiagnosis when screening with prostate-specific antigen for prostate cancer. I think that this paper actually shows that overdiagnosis is a serious problem when screening with mammography.
  4 in total

1.  Lead-time and overdiagnosis estimation in neuroblastoma screening.

Authors:  Claudia Spix; Jörg Michaelis; Frank Berthold; Rudolf Erttmann; Johannes Sander; Freimut H Schilling
Journal:  Stat Med       Date:  2003-09-30       Impact factor: 2.373

2.  Cochrane review on screening for breast cancer with mammography.

Authors:  O Olsen; P C Gøtzsche
Journal:  Lancet       Date:  2001-10-20       Impact factor: 79.321

3.  Overdiagnosis due to prostate-specific antigen screening: lessons from U.S. prostate cancer incidence trends.

Authors:  Ruth Etzioni; David F Penson; Julie M Legler; Dante di Tommaso; Rob Boer; Peter H Gann; Eric J Feuer
Journal:  J Natl Cancer Inst       Date:  2002-07-03       Impact factor: 13.506

4.  Breast cancer incidence after the start of mammography screening in Denmark.

Authors:  A H Olsen; A Jensen; S H Njor; E Villadsen; W Schwartz; I Vejborg; E Lynge
Journal:  Br J Cancer       Date:  2003-02-10       Impact factor: 7.640

  4 in total
  3 in total

1.  Reduction in mortality from breast cancer: presentation of benefits and harms needs to be balanced.

Authors:  Peter C Gøtzsche; Hazel Thornton; Karsten J Jørgensen
Journal:  BMJ       Date:  2005-04-30

2.  Most breast cancer screening trials have a flawed design.

Authors:  Nishant Gurnani; Anurag Srivastava
Journal:  Indian J Surg       Date:  2011-10-25       Impact factor: 0.656

3.  Higher breast cancer prevalence associated with higher socioeconomic status in the South Korean population; Has it resulted from overdiagnosis?

Authors:  Seong-Woo Choi; So-Yeon Ryu; Mi-Ah Han; Jong Park
Journal:  PLoS One       Date:  2018-07-12       Impact factor: 3.240

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.